Favipiravir permanently registered in Russia for COVID-19 treatment
MOSCOW. KAZINFORM - Favipiravir, a drug used to treat COVID-19, has received permanent registration in Russia, Russian Deputy Health Minister Viktor Fisenko said on Thursday, TASS reports.
«Following a sped-up procedure, we have greenlit circulation of prevention drugs (vaccines), antiviral therapy drugs - Favipiravir, Remdesivir, and a drug used to mitigate a cytokine storm - Levilimab,» he said, adding that Favipiravir has received a permanent registration certificate.
Earlier, the Russian Federal Service for Surveillance in Healthcare informed that Russia had registered three drugs based on Favipiravir: Avifavir, Areplivir and Coronavir. The watchdog has not received any complaints of non-specific motor disorders during the use of the drugs.
- 822 kids receive treatment for COVID-19 in Kazakhstan
- ANSA: Covid: 28,352 new cases in 24 hrs, 827 deaths
- N. Korea enforces home classes for kids amid COVID-19 concerns
- Record-high 90,000 Americans hospitalized with COVID-19 amid Thanksgiving
-
Sputnik V trials in Belarus show vaccine efficacy of about 95%
-
US: Online sales on Thanksgiving Day hit record $5.1B
- Speeches of the President of the Republic of Kazakhstan
- President's Address to the Nation
- Development of the President's Message
- Foreign Mass Media about Kazakhstan
- World and Crisis
